We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+0.05%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$3.55B
AUM Growth
+$59.4M
Cap. Flow
+$77M
Cap. Flow %
2.17%
Top 10 Hldgs %
49.57%
Holding
665
New
156
Increased
155
Reduced
111
Closed
128

Top Buys

Rank Stock Value
1
HCP
HashiCorp, Inc. Class A Common Stock
HCP
+$138M
2
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
+$131M
3
EDR
Endeavor Group Holdings, Inc.
EDR
+$127M
4
MRO
Marathon Oil Corporation
MRO
+$123M
5
CHX
ChampionX
CHX
+$98.3M

Top Sells

Rank Stock Value
1
PXD
Pioneer Natural Resource Co.
PXD
+$638M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$51.2M
3
DFS
Discover Financial Services
DFS
+$45.1M
4
SCRM
Screaming Eagle Acquisition Corp. Class A Ordinary Shares
SCRM
+$18.4M
5
NSC icon
Norfolk Southern
NSC
+$17.7M

Sector Composition

Rank Sector Weight
1 Energy 26.53%
2 Technology 21.03%
3 Healthcare 14.68%
4 Industrials 8.19%
5 Materials 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OFIX icon
601
CALL
Orthofix Medical
OFIX
$419M
– –
-50,000
Closed -$37.5K
ORCL icon
602
Oracle
ORCL
$423B
– –
-52,486
Closed -$6.59M
ORIC icon
603
CALL
Oric Pharmaceuticals
ORIC
$1.4B
– –
-80,000
Closed -$50K
PANW icon
604
Palo Alto Networks
PANW
$297B
– –
-2,800
Closed -$398K
PATH icon
605
UiPath
PATH
$7.8B
– –
-50,000
Closed -$1.13M
PHAT icon
606
Phathom Pharmaceuticals
PHAT
$692M
– –
-28,583
Closed -$304K
PLTR icon
607
Palantir
PLTR
$413B
– –
-10,000
Closed -$230K
PMVP icon
608
PMV Pharmaceuticals
PMVP
$63.5M
– –
-56,852
Closed -$96.6K
PRAX icon
609
CALL
Praxis Precision Medicines
PRAX
$10.1B
– –
-27,100
Closed -$238K
PRCT icon
610
Procept Biorobotics
PRCT
$1.17B
– –
-13,217
Closed -$653K
PTCT icon
611
CALL
PTC Therapeutics
PTCT
$6.12B
– –
-20,000
Closed -$44.5K
QTRX icon
612
Quanterix
QTRX
$190M
– –
-16,794
Closed -$396K
RAPT
613
DELISTED
RAPT Therapeutics
RAPT
– –
-9,136
Closed -$422K
RDN icon
614
PUT
Radian Group
RDN
$4.91B
– –
-59,000
Closed -$22.8K
RLAY icon
615
Relay Therapeutics
RLAY
$4.31B
– –
-100,039
Closed -$830K
SNDX icon
616
CALL
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-77,400
Closed -$44.9K
SRRK icon
617
Scholar Rock
SRRK
$6.44B
– –
-41,378
Closed -$735K
STX icon
618
Seagate
STX
$184B
– –
-17,500
Closed -$1.63M
TAL icon
619
TAL Education Group
TAL
$6.87B
– –
-312,000
Closed -$3.54M
TRML
620
PUT
DELISTED
Tourmaline Bio
TRML
– –
-20,000
Closed -$345K
TSLA icon
621
PUT
Tesla
TSLA
$1.3T
– –
-50,000
Closed -$170K
TTD icon
622
Trade Desk
TTD
$6.49B
– –
-11,000
Closed -$962K
TV icon
623
CALL
Televisa
TV
$1.49B
– –
-73,500
Closed -$132K
VERA icon
624
CALL
Vera Therapeutics
VERA
$2.36B
– –
-20,000
Closed -$97K
VNET
625
VNET Group
VNET
$2.09B
– –
-150,000
Closed -$233K
23 24
25
26 27

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return

UBS O'Connor's Q2 2024 Portfolio in Review

As of Q2 2024, UBS O'Connor held 665 positions worth $3.55B, up 1.7% from $3.49B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

UBS O'Connor's Q2 2024 filing shows 156 new, 155 increased, 111 reduced and 128 closed positions. Its largest new stake was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M. The largest sale was Pioneer Natural Resource Co., an estimated $638M.

By sector, the portfolio is most concentrated in Energy at 27% of assets, down from 34% a quarter earlier, followed by Technology and Healthcare.

  • UBS O'Connor's largest Q2 2024 buy was Endeavor Group Holdings, Inc.: 4,789,930 shares worth $129M.
  • UBS O'Connor added most to HashiCorp, Inc. Class A Common Stock in Q2 2024, an estimated $138M increase.
  • UBS O'Connor's biggest Q2 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $51.2M.
  • UBS O'Connor fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $638M.
  • UBS O'Connor's ten largest holdings make up 50% of its $3.55B portfolio in Q2 2024.
  • UBS O'Connor opened 156 new positions and closed 128 in Q2 2024.
  • UBS O'Connor's portfolio value rose 1.7% quarter-over-quarter to $3.55B.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.